Przewlekła białaczka szpikowa
Charakterystyka, pielęgnacja i opieka

Przewlekła białaczka szpikowa (CML) to klonalna mieloproliferacyjna choroba hematologiczna charakteryzująca się obecnością chromosomu Philadelphia [t(9;22)] i genu fuzyjnego BCR-ABL, kodującego patologicznie aktywną kinazę tyrozynową p210. CML przebiega w trzech fazach: przewlekłej, akceleracji i blastycznej, z których większość pacjentów diagnozowana jest w fazie przewlekłej, często bezobjawowo lub z niespecyficznymi symptomami takimi jak anemia, poty nocne, powiększenie śledziony czy skłonność do krwawień. Diagnostyka opiera się na morfologii krwi, badaniu szpiku, cytogenetyce i molekularnym wykrywaniu BCR-ABL. Monitorowanie terapii obejmuje regularne badania molekularne co 3-6 miesięcy w celu oceny odpowiedzi na leczenie i wykrycia ewentualnej oporności. Standardem leczenia są inhibitory kinazy tyrozynowej (TKI) takie jak imatynib, dazatynib, nilotynib, bosutynib, ponatynib i asciminib, które znacząco poprawiły rokowanie, umożliwiając długotrwałą remisję u ponad 90% pacjentów. Przeszczep allogeniczny komórek macierzystych pozostaje jedyną potencjalnie leczącą metodą, stosowaną w przypadku oporności na TKI lub w fazie zaawansowanej choroby, jednak wiąże się z wysokim ryzykiem powikłań i śmiertelności (15-20%).

  1. Przewlekła białaczka szpikowa – charakterystyka choroby
  2. Objawy i rozpoznanie przewlekłej białaczki szpikowej
    1. Diagnostyka CML
  3. Fazy przewlekłej białaczki szpikowej
  4. Leczenie przewlekłej białaczki szpikowej
    1. Terapia inhibitorami kinazy tyrozynowej (TKI)
    2. Przeszczep komórek macierzystych
    3. Inne metody leczenia
  5. Opieka pielęgniarska w przewlekłej białaczce szpikowej
    1. Priorytety w opiece pielęgniarskiej
    2. Diagnozy pielęgniarskie w CML
    3. Interwencje pielęgniarskie
    4. Edukacja pacjenta
  6. Monitorowanie i obserwacja w CML
  7. Wsparcie psychospołeczne i jakość życia
  8. Rokowanie i perspektywy leczenia CML
  9. Wzmacnianie pozycji pacjenta w zarządzaniu CML
  10. Podejście multidyscyplinarne w opiece nad pacjentem z CML
  11. Podsumowanie opieki pielęgniarskiej w CML
    1. Kolejne rozdziały

Przewlekła białaczka szpikowa – charakterystyka choroby

Przewlekła białaczka szpikowa (Chronic Myelogenous Leukemia, CML) to nowotwór krwi i szpiku kostnego, który rozwija się powoli, charakteryzujący się nadmiernym wytwarzaniem białych krwinek, szczególnie granulocytów. CML stanowi około 14-20% wszystkich przypadków białaczek i występuje głównie u osób dorosłych, rzadko u dzieci. Choroba pojawia się, gdy pluripotencjalna komórka macierzysta ulega złośliwej transformacji i klonalnej mieloproliferacji, prowadząc do wyraźnej nadprodukcji dojrzałych i niedojrzałych granulocytów.123

Przewlekła białaczka szpikowa charakteryzuje się obecnością chromosomu Philadelphia, powstałego w wyniku wzajemnej translokacji między chromosomami 9 i 22 [t(9;22)]. Translokacja ta prowadzi do powstania genu fuzyjnego BCR-ABL, którego produkt – białko p210 o zaburzonej aktywności kinazy tyrozynowej – odgrywa kluczową rolę w patogenezie CML. Wszystkie przypadki CML są spowodowane genem fuzyjnym BCR::ABL1, który nie występuje w normalnych komórkach krwi.12

CML nie ingeruje całkowicie w rozwój dojrzałych krwinek czerwonych, białych i płytek krwi. Dlatego przewlekła faza CML jest ogólnie mniej ciężka niż ostra białaczka. U większości pacjentów z CML choroba jest diagnozowana podczas rutynowego badania fizykalnego lub badania krwi, a objawy mogą początkowo nie występować.12

Objawy i rozpoznanie przewlekłej białaczki szpikowej

Osoby z przewlekłą białaczką szpikową mogą początkowo nie mieć żadnych objawów. Często choroba jest wykrywana podczas rutynowych badań krwi. Objawy CML rozwijają się stopniowo i gdy się pojawią, pacjenci mogą zgłaszać:12

  • Zmęczenie i osłabienie (związane z anemią)
  • Poty nocne
  • Częste infekcje
  • Utratę wagi
  • Gorączkę
  • Dyskomfort w jamie brzusznej z powodu powiększonej śledziony
  • Łatwe siniaczenie lub krwawienie (z powodu małopłytkowości)

123

Wiele objawów CML występuje, ponieważ komórki białaczkowe wypierają zdrowe krwinki czerwone, białe krwinki i płytki krwi ze szpiku kostnego. Anemia, czyli niedobór czerwonych krwinek, może powodować osłabienie, zmęczenie i duszność. Brak prawidłowych białych krwinek może zwiększyć ryzyko infekcji, a brak płytek krwi może prowadzić do nadmiernego siniaczenia lub krwawienia. Objawy mogą również wystąpić, ponieważ komórki CML gromadzą się w narządach, takich jak śledziona.1

Diagnostyka CML

Rozpoznanie CML opiera się na badaniach krwi i szpiku kostnego. Podstawowe badania diagnostyczne obejmują:12

  • Morfologię krwi z rozmazem – często wykazuje podwyższoną liczbę białych krwinek
  • Badanie szpiku kostnego
  • Analizę chromosomową (kariotypowanie) – w celu wykrycia chromosomu Philadelphia
  • Badania molekularne w kierunku wykrycia genu fuzyjnego BCR-ABL

12

Diagnoza przewlekłej białaczki limfocytowej wymaga co najmniej 5000 na μL (5 × 10^9 na L) monoklonalnych limfocytów B w rozmazie krwi obwodowej i powinna być potwierdzona cytometrią przepływową. Przewlekła białaczka szpikowa charakteryzuje się identyfikacją chromosomu Philadelphia poprzez badania cytogenetyczne lub molekularne szpiku kostnego lub rozmazu krwi obwodowej.1

Fazy przewlekłej białaczki szpikowej

CML ma trzy fazy, które charakteryzują progresję choroby:1

  1. Faza przewlekła – najwcześniejsza i najłagodniejsza faza, w której choroba rozwija się powoli. Większość pacjentów jest diagnozowana w tej fazie. Komórki białaczkowe dzielą się i rozprzestrzeniają wolniej, a objawy mogą być łagodne lub nieobecne.
  2. Faza akceleracji – choroba zaczyna postępować szybciej, liczba komórek blastycznych wzrasta, a objawy stają się bardziej widoczne.
  3. Faza blastyczna (kryza blastyczna) – najbardziej zaawansowana faza, przypominająca ostrą białaczkę. Komórki blastyczne szybko się namnażają i rozprzestrzeniają do innych tkanek i narządów.

12

Gdy CML znajduje się w fazie przewlekłej, objawy mogą nie występować, a większość osób może prowadzić normalne życie. Leczenie polega na przyjmowaniu tabletek w domu. Regularne badania krwi są niezbędne do sprawdzenia, jak dobrze działa leczenie.1

Leczenie przewlekłej białaczki szpikowej

Głównym celem leczenia CML jest eliminacja komórek krwi zawierających gen BCR-ABL. U większości osób leczenie rozpoczyna się od terapii celowanej, która może pomóc osiągnąć długotrwałą remisję choroby.12

Terapia inhibitorami kinazy tyrozynowej (TKI)

Podstawową metodą leczenia CML są inhibitory kinazy tyrozynowej (TKI), które blokują białko wytwarzane przez gen BCR-ABL, hamując niekontrolowane namnażanie się komórek białaczkowych. TKI zrewolucjonizowały leczenie CML, przekształcając ją z choroby zagrażającej życiu w stan przewlekły, możliwy do opanowania u większości pacjentów.12

Do najczęściej stosowanych inhibitorów kinazy tyrozynowej w leczeniu CML należą:12

12

Najczęstsze działania niepożądane związane z leczeniem TKI obejmują: obrzęki skóry, nudności, skurcze mięśni, zmęczenie, biegunkę i wysypki skórne. Ważne jest, aby nie przerywać leczenia bez konsultacji z lekarzem, nawet w przypadku wystąpienia działań niepożądanych.12

Odpowiedź na leczenie TKI jest najważniejszym czynnikiem prognostycznym dla pacjentów z CML. Badania krwi w kierunku obecności genu BCR-ABL są wykorzystywane do monitorowania skuteczności terapii celowanej.12

Przeszczep komórek macierzystych

Przeszczep szpiku kostnego, znany również jako przeszczep komórek macierzystych, jest jedynym leczeniem, które może wyleczyć przewlekłą białaczkę szpikową. Jest to jednak procedura wysokiego ryzyka, ze wskaźnikiem śmiertelności związanej z leczeniem na poziomie 15-20%, dlatego zazwyczaj jest zarezerwowana dla osób, które nie odpowiadają na leczenie TKI.12

Allogeniczny przeszczep komórek macierzystych, ze względu na swoją toksyczność i skuteczność inhibitorów kinazy tyrozynowej, jest stosowany selektywnie. Przeszczep jest zarezerwowany dla pacjentów z CML w fazie akceleracji lub blastycznej, oporną na inhibitory BCR-ABL. Przeszczep może być leczeniem prowadzącym do wyleczenia.1

Inne metody leczenia

W niektórych przypadkach stosowane są również inne metody leczenia:

  • Chemioterapia – kiedyś była powszechnym leczeniem CML, jednak TKI są obecnie znane jako bardziej skuteczne, więc chemioterapia będzie stosowana tylko wtedy, gdy TKI nie działają lub jako część przeszczepu komórek macierzystych.12
  • Terapia biologiczna (immunoterapia) – wykorzystuje układ odpornościowy pacjenta do walki z rakiem. Substancje wytwarzane przez organizm lub w laboratorium służą do wzmocnienia, ukierunkowania lub przywrócenia naturalnych mechanizmów obronnych organizmu przeciwko nowotworowi.1
  • Splenektomia – chirurgiczne usunięcie śledziony może być konieczne w niektórych przypadkach.1

Opieka pielęgniarska w przewlekłej białaczce szpikowej

Pielęgniarki odgrywają kluczową rolę we wspieraniu pacjentów z przewlekłą białaczką szpikową poprzez zapewnienie kompleksowej opieki, zarządzanie objawami i edukację pacjentów podczas całego procesu leczenia.12

Priorytety w opiece pielęgniarskiej

Główne priorytety opieki pielęgniarskiej w CML obejmują:12

  • Minimalizowanie ryzyka infekcji poprzez kontrolę zakażeń
  • Zarządzanie działaniami niepożądanymi chemioterapii i terapii celowanej
  • Kontrola bólu i dyskomfortu
  • Zapewnienie wsparcia emocjonalnego
  • Edukacja zdrowotna pacjenta i rodziny
  • Zarządzanie objętością płynów
  • Zwiększanie tolerancji na aktywność
  • Monitorowanie pod kątem potencjalnych powikłań

123

Diagnozy pielęgniarskie w CML

Najczęstsze diagnozy pielęgniarskie u pacjentów z CML to:12

  • Ryzyko infekcji związane z leukopenią i leczeniem immunosupresyjnym
  • Ryzyko krwawienia związane z małopłytkowością i supresją szpiku kostnego
  • Zmęczenie związane z anemią i efektami chemioterapii
  • Zaburzony obraz ciała związany z utratą włosów, utratą wagi i bladością wynikającą z leczenia białaczki
  • Ból ostry związany z powiększonymi narządami, węzłami chłonnymi i szpikiem kostnym wypełnionym komórkami białaczkowymi
  • Nietolerancja aktywności związana z ogólnym osłabieniem, zmniejszonymi zapasami energii i zwiększonym tempem metabolizmu
  • Deficyt wiedzy dotyczący choroby, rokowania, leczenia i samoopieki

123

Interwencje pielęgniarskie

Oto kluczowe interwencje pielęgniarskie w opiece nad pacjentem z CML:12

  1. Zapobieganie infekcjom:
    • Wdrażanie ścisłych protokołów kontroli zakażeń
    • Stosowanie środków ostrożności u pacjentów z neutropenią
    • Monitorowanie pod kątem oznak infekcji (gorączka, dreszcze, nowe objawy)
    • Edukacja pacjenta na temat higieny rąk i unikania kontaktu z potencjalnymi źródłami infekcji
    • Zapewnienie odpowiedniego odżywiania w celu wzmocnienia układu odpornościowego
  2. Zarządzanie ryzykiem krwawienia:
    • Monitorowanie liczby płytek krwi i badań koagulologicznych
    • Wdrażanie środków ostrożności przeciw krwawieniu
    • Ocena pod kątem wybroczyn, siniaków i krwawienia z dziąseł
    • Edukacja pacjenta na temat unikania aktywności, które mogą prowadzić do urazów
    • Podawanie preparatów krwiopochodnych zgodnie z zaleceniami
  3. Łagodzenie zmęczenia:
    • Zapewnienie strategii oszczędzania energii
    • Planowanie częstych okresów odpoczynku
    • Zachęcanie do małych, bogatych w składniki odżywcze posiłków
    • Monitorowanie poziomów hemoglobiny
  4. Wsparcie emocjonalne:
    • Oferowanie usług doradztwa
    • Zachęcanie do uczestnictwa w grupach wsparcia dla osób z białaczką
    • Pomoc pacjentom w rozwijaniu strategii radzenia sobie z chorobą
    • Wspieranie w kwestiach związanych z obrazem ciała, w tym z zarządzaniem utratą włosów
  5. Monitorowanie i ocena:
    • Regularne monitorowanie morfologii krwi z rozmazem
    • Obserwacja pod kątem oznak zwiększonego ryzyka infekcji (neutropenia), anemii i małopłytkowości
    • Ocena psychospołeczna: określenie mechanizmów radzenia sobie pacjenta, systemu wsparcia i potrzeby wsparcia psychologicznego

1234

Edukacja pacjenta

Edukacja pacjenta jest kluczowym elementem opieki pielęgniarskiej w CML i powinna obejmować:12

  • Informacje o znaczeniu zapobiegania infekcjom i jak rozpoznawać ich oznaki (np. gorączka)
  • Omówienie potencjalnych działań niepożądanych chemioterapii i terapii celowanych, w tym nudności, wypadania włosów i zwiększonego ryzyka krwawienia
  • Dostarczanie informacji o przeszczepie komórek macierzystych, jeśli dotyczy, w tym o procesie i potencjalnych powikłaniach
  • Zachęcanie opiekunów do zapewnienia wsparcia emocjonalnego i pomocy w zarządzaniu codziennymi potrzebami pacjenta, w tym transportem na leczenie i zapewnieniem przestrzegania zaleceń dotyczących leków
  • Informowanie o znaczeniu regularnego monitorowania i badań kontrolnych
  • Edukacja na temat zdrowego stylu życia, diety i aktywności fizycznej

12

Monitorowanie i obserwacja w CML

Regularne monitorowanie jest kluczowe dla skutecznego leczenia CML i obejmuje:12

  • Regularne badania krwi w celu monitorowania odpowiedzi na leczenie
  • Badania molekularne w celu wykrycia obecności genu BCR-ABL
  • Amerykańska NCCN (National Comprehensive Cancer Network) i European LeukemiaNet zalecają monitorowanie co 3-6 miesięcy w celu potwierdzenia przestrzegania terapii i zapewnienia, że kamienie milowe leczenia są osiągane i utrzymywane
  • Wizyty kontrolne u onkologa w celu oceny odpowiedzi na leczenie i ewentualnych działań niepożądanych

12

Dla wielu osób przewlekła białaczka szpikowa jest chorobą, z którą będą żyć przez lata. Wielu będzie kontynuować leczenie terapią celowaną przez czas nieokreślony. Dlatego bardzo ważne jest przestrzeganie zaleceń dotyczących monitorowania i kontroli.12

Wsparcie psychospołeczne i jakość życia

Pacjenci z CML często doświadczają znacznego stresu emocjonalnego związanego z diagnozą przewlekłej choroby nowotworowej. Wsparcie psychospołeczne jest istotnym elementem kompleksowej opieki.12

Posiadanie przewlekłej choroby może być emocjonalnie przytłaczające. Ważne jest, aby pacjenci rozmawiali o swoich uczuciach z zespołem opieki zdrowotnej i w razie potrzeby prosili o skierowanie do doradcy lub innego specjalisty, z którym mogą porozmawiać.12

Grupy wsparcia i rozmowy z innymi osobami w podobnej sytuacji mogą pomóc zmniejszyć stres, niepokój i poczucie izolacji. Zrozumienie swojej choroby i jej leczenia również może pomóc pacjentom lepiej radzić sobie z sytuacją, umożliwiając im aktywne uczestnictwo w podejmowaniu decyzji dotyczących leczenia.12

Rokowanie i perspektywy leczenia CML

Postępy w leczeniu znacznie poprawiły rokowanie osób z przewlekłą białaczką szpikową. Większość pacjentów może osiągnąć remisję i żyć przez wiele lat po diagnozie.12

Od czasu wprowadzenia terapii inhibitorami kinazy tyrozynowej w 2001 roku CML została przekształcona z choroby zagrażającej życiu w przewlekły stan możliwy do opanowania u większości pacjentów. Ludzie żyją dłużej z CML i doświadczają mniej działań niepożądanych leczenia.1

W niektórych przypadkach CML może stać się oporna na leczenie. Jednak nawet wtedy dostępne są alternatywne opcje terapeutyczne, w tym inne inhibitory kinazy tyrozynowej drugiej i trzeciej generacji oraz przeszczep komórek macierzystych.12

Od 2002 roku oczekiwana długość życia u osób z CML znacznie wzrosła. Obecnie ponad 90% pacjentów osiąga długotrwałe remisje dzięki nowoczesnym metodom leczenia.1

Wzmacnianie pozycji pacjenta w zarządzaniu CML

Wzmacnianie pozycji pacjenta to podejście do opieki skoncentrowane na pacjencie, w którym personel medyczny wspiera naturalne zdolności pacjentów do samozarządzania i włącza cele pacjenta dotyczące terapii do ogólnego planu leczenia. Standardowa opieka w przewlekłej białaczce szpikowej wymaga dożywotniego przyjmowania leków doustnych i regularnych kontroli.1

Sukces leczenia CML zależy więc od wysokiego stopnia zaangażowania i motywacji pacjenta, a także ścisłej współpracy między pacjentami a personelem medycznym. Pielęgniarki onkologiczne mogą wspierać pacjentów z CML od momentu diagnozy do zakończenia leczenia, aby zapewnić im utrzymanie wysokiego poziomu zaangażowania w opiekę.1

Warto podkreślić, że zrozumienie swojej choroby i jej leczenia może pomóc pacjentom lepiej radzić sobie z sytuacją. Oznacza to, że mogą oni omawiać leczenie, badania i kontrole ze swoimi lekarzami i pielęgniarkami oraz aktywnie uczestniczyć w podejmowaniu decyzji. To może sprawić, że poczują się pewniej i bardziej kontrolują sytuację.1

Podejście multidyscyplinarne w opiece nad pacjentem z CML

Opieka nad pacjentem z CML wymaga podejścia multidyscyplinarnego, angażującego różnych specjalistów opieki zdrowotnej.12

Oprócz onkologa, inni członkowie zespołu multidyscyplinarnego również muszą przekazywać pacjentowi kluczowe informacje dotyczące leczenia. Pielęgniarki powinny skutecznie monitorować i zarządzać potencjalnymi działaniami niepożądanymi oraz edukować pacjentów o znaczeniu przyjmowania TKI zgodnie z zaleceniami i zgłaszania działań niepożądanych.1

Zespół opieki zdrowotnej w przypadku białaczki łączy zespół wielospecjalistyczny specjalistów zajmujących się leczeniem białaczki, nowotworów krwi i rzadkich form zaburzeń krwi. Koordynatorzy opieki multidyscyplinarnej to wyspecjalizowane pielęgniarki, które zapewniają indywidualne wsparcie, prowadząc pacjenta przez proces leczenia nowotworowego. Ci koordynatorzy służą jako punkt kontaktowy, pomagając zarządzać opieką, od pierwszej wizyty po wizyty kontrolne.1

Zaangażowanie farmaceuty onkologicznego jest niezbędne do zrozumienia pełnego profilu leków poszczególnych pacjentów, omówienia potencjalnych interakcji między lekami oraz współpracy z pacjentami w celu maksymalizacji korzyści z terapii TKI.1

Podsumowanie opieki pielęgniarskiej w CML

Pielęgniarki odgrywają kluczową rolę w opiece nad pacjentami z przewlekłą białaczką szpikową, zapewniając kompleksową opiekę obejmującą zarządzanie objawami, edukację pacjenta, wsparcie emocjonalne i monitorowanie skuteczności leczenia oraz potencjalnych działań niepożądanych.12

Dzięki wprowadzeniu inhibitorów kinazy tyrozynowej (TKI) oraz zaawansowanych metod monitorowania, przewlekła białaczka szpikowa przekształciła się z choroby zagrażającej życiu w stan przewlekły, możliwy do opanowania. Pielęgniarki onkologiczne, które posiadają wiedzę na temat nowych terapii w CML, mogą być skutecznym wsparciem dla swoich pacjentów.12

Holistyczne podejście do opieki, uwzględniające nie tylko aspekty fizyczne, ale także psychospołeczne potrzeby pacjenta, jest niezbędne do zapewnienia najlepszej możliwej jakości życia osób z CML. Wzmacnianie pozycji pacjenta poprzez edukację, wsparcie i zachęcanie do aktywnego uczestnictwa w procesie leczenia znacząco wpływa na wyniki kliniczne i ogólne doświadczenie pacjenta.12

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

  1. 11.04.2026
  2. www.leksykon.com.pl

Materiały źródłowe

  • #1 Chronic Myelogenous Leukemia | Oncology Nursing Society
    https://www.ons.org/publications-research/cjon/9/5/chronic-myelogenous-leukemia
    Chronic myelogenous leukemia (CML) represents about 14% of all leukemias and occurs with a frequency of about 1 in 100,000. […] Symptoms include fatigue, weight loss, sweating, and abdominal discomfort from an enlarged spleen. […] Most patients are diagnosed during the chronic phase. […] Imatinib mesylate, a tyrosine kinase inhibitor, was approved in 2002 for the treatment of all phases of CML. […] Because of its effectiveness, imatinib has become the treatment of choice for most patients with CML. […] Stem cell transplantation also is an option for eligible patients. […] Oncology nurses who are knowledgeable about new therapies for CML can be effective resources for their patients.
  • #1 Optimizing Patient Care in Chronic Phase Chronic Myelogenous Leukemia: A Multidisciplinary Approach in: Journal of the National Comprehensive Cancer Network Volume 14 Issue suppl_1 (2016)
    https://jnccn.org/view/journals/jnccn/14/suppl_1/article-pS-1.xml?rskey=EaEf2s&result=1&print
    Chronic myelogenous leukemia (CML) is characterized by the presence of the Philadelphia chromosome arising from a reciprocal translocation between chromosomes 9 and 22 [t(9;22)]. This translocation results in the formation of the BCR-ABL fusion gene. The product of this fusion gene, p210, a protein with deregulated tyrosine kinase activity, plays a central role in the pathogenesis of CML. Tyrosine kinase inhibitor (TKI) therapy with small molecule inhibitors of BCR-ABL tyrosine kinase has significantly reduced the annual mortality rate among patients with CML. […] The importance of monitoring BCR-ABL1 level and response milestones, adherence to imatinib therapy, and the common adverse effects of imatinib (eg, edema, diarrhea, muscle aches) were discussed with the patient. The patient was also counseled by the nurse practitioner to avoid grapefruit juice while taking imatinib and was also advised about the potential interactions of imatinib with other medications that the patient was taking at the time of therapy.
  • #1 Chronic Myeloid Leukemia (CML) | Learn What Is CML | LLS
    https://www.lls.org/leukemia/chronic-myeloid-leukemia
    Chronic myeloid leukemia (CML) is also called chronic myelogenous leukemia, chronic granulocytic leukemia and chronic myelocytic leukemia. CML is one of four main types of leukemia. […] Most CML patients are treated with daily oral drug therapy. […] Since the introduction of tyrosine kinase inhibitor (TKI) therapy in 2001, CML has been transformed from a life-threatening disease to a manageable chronic condition for most patients. People are living longer with CML and experiencing fewer treatment side effects. […] Make sure your doctor continually monitors your response to medication, which is essential to bringing your CML under control. […] CML doesn’t completely interfere with the development of mature red cells, white cells and platelets. Therefore, chronic phase CML is generally less severe than acute leukemia. […] All cases of CML are caused by the BCR::ABL1 fusion gene. This gene is not found in normal blood cells. […] For most people who have chronic myeloid leukemia (CML), there are no obvious reasons why they develop the disease.
  • #1 Chronic Myeloid Leukemia (CML) | Signs and Symptoms of CML | LLS
    https://www.lls.org/leukemia/chronic-myeloid-leukemia/signs-and-symptoms
    People who have chronic myeloid leukemia (CML) may not have any symptoms at first. Often, patients learn they have CML after a routine physical exam or a blood test. CML signs and symptoms tend to develop gradually. Those with symptoms often report experiencing: […] Many signs and symptoms of CML occur because the CML cells crowd out the bone marrows healthy red blood cells, white blood cells and platelets. […] Anemia is a lack of red blood cells that can cause weakness, fatigue and shortness of breath. A lack of normal white blood cells can increase the risk of infection, and a lack of platelets can lead to excessive bruising or bleeding. Symptoms may also occur because CML cells accumulate in organs such as the spleen. Some patients may have a high platelet count.
  • #1 Leukemia: Nursing Diagnoses, Care Plans, Assessment & Interventions | NurseTogether
    https://www.nursetogether.com/leukemia-nursing-diagnosis-care-plan/
    Leukemia is classified according to the rate at which the condition progresses and whether the leukemia cells come from lymphoid or myeloid cells. […] Chronic Myelogenous Leukemia (CML) occurs mainly in adults. It frequently does not show symptoms early on, but the patient may exhibit night sweats, frequent infections, weight loss, fatigue, and fever later on. […] Nurses support patients with leukemia by providing supportive care, especially for those who are undergoing chemotherapy, radiation, and other biologic therapies. It is essential to manage and prevent complications, provide comfort measures, patient and family education, and continuous emotional support. […] Nursing interventions and care are essential for the patients recovery. […] Administer growth factors as ordered. Administer growth factors as ordered before harvesting stem cells for a stem cell transplant. Growth factors stimulate the development of new blood cells in the bone marrow. Granulocyte colony-stimulating factor stimulates the production of WBCs, erythropoietin stimulates new RBCs, and thrombopoietin stimulates platelet growth.
  • #1 Chronic Myelogenous Leukemia – CML | Hematology-Oncology Associates of CNY
    https://www.hoacny.com/our-services/cancers-we-treat/chronic-myelogenous-leukemia-cml
    Chronic myeloid leukemia is a disease in which the bone marrow makes too many white blood cells. […] Signs and symptoms of chronic myeloid leukemia include weight loss and tiredness. […] Tests that examine the blood and bone marrow are used to diagnose chronic myeloid leukemia. […] Certain factors affect prognosis (chance of recovery) and treatment options. […] There are different types of treatment for patients with chronic myeloid leukemia. […] Treatment for chronic myeloid leukemia may cause side effects. […] Follow-up care may be needed. […] Treatment of chronic phase chronic myeloid leukemia may include: targeted therapy (asciminib, imatinib mesylate, nilotinib, dasatinib, bosutinib) and allogeneic bone marrow transplant or stem cell transplant. […] Treatment of accelerated phase chronic myeloid leukemia may include: targeted therapy (bosutinib) and targeted therapy (imatinib mesylate) followed by allogeneic stem cell transplant.
  • #1 Leukemia: What Primary Care Physicians Need to Know | AAFP
    https://www.aafp.org/pubs/afp/issues/2023/0400/leukemia.html
    Asymptomatic, early-stage chronic lymphocytic leukemia (i.e., absence of anemia and thrombocytopenia and less than three areas of lymph node involvement) may be monitored without treatment. Progression to active-stage disease is defined by worsening constitutional symptoms, lymphocytosis, thrombocytopenia, anemia, progressive lymphadenopathy, or hepatosplenomegaly and requires treatment. […] Hyperleukocytosis (more than 100,000 per L [100 109 per L] white blood cells) is a hallmark of chronic myelogenous and chronic lymphocytic leukemia. A peripheral blood smear should be obtained if hyperleukocytosis is present on complete blood count, especially when associated with anemia, thrombocytopenia, thrombocytosis, hepatosplenomegaly, lymphadenopathy, or unexplained constitutional symptoms. […] The diagnosis of chronic lymphocytic leukemia requires at least 5,000 per L (5 109 per L) monoclonal B lymphocytes on a peripheral blood smear and should be confirmed with flow cytometry. Chronic myelogenous leukemia is characterized by identification of the Philadelphia chromosome through cytogenic or molecular testing of bone marrow or peripheral blood smear.
  • #1 Chronic myeloid leukaemia (CML) | Macmillan Cancer Support
    https://www.macmillan.org.uk/cancer-information-and-support/leukaemia/chronic-myeloid-leukaemia-cml
    Chronic myeloid leukaemia (also called CML or CML leukemia) is a cancer of the blood cells. […] CML usually develops slowly. There are three phases of CML. […] When CML is in the chronic phase, there may be no symptoms and most people can have a normal life. Treatment is with tablets you can take at home. You will have regular blood tests to check how well the treatment is working. […] A team of specialists will meet to discuss the best possible treatment for you. This is called a multidisciplinary team (MDT). […] Your cancer doctor or specialist nurse will explain the different treatments and their side effects. They will also talk to you about certain things to think about when making treatment decisions. […] If you have treatment with a TKI, you will be monitored by your healthcare team every 1 to 2 weeks.
  • #1 Chronic myelogenous leukemia – Diagnosis and treatment – Mayo Clinic
    https://www.mayoclinic.org/diseases-conditions/chronic-myelogenous-leukemia/diagnosis-treatment/drc-20352422
    Our caring team of Mayo Clinic experts can help you with your chronic myelogenous leukemia-related health concerns […] The goal of chronic myelogenous leukemia treatment is to eliminate the blood cells that contain the BCR-ABL gene. For most people, treatment begins with targeted therapy that may help achieve a long-term remission of the disease. […] TKIs are the initial treatment for people diagnosed with chronic myelogenous leukemia. Side effects of these targeted medicines include swelling or puffiness of the skin, nausea, muscle cramps, fatigue, diarrhea, and skin rashes. […] A bone marrow transplant, also called a stem cell transplant, is the only treatment that can cure chronic myelogenous leukemia. However, it’s usually reserved for people who haven’t been helped by other treatments.
  • #1 Chronic myeloid leukemia | Conditions | UCSF Health
    https://www.ucsfhealth.org/conditions/chronic-myeloid-leukemia
    Tyrosine kinase inhibitors (TKIs) are drugs used for targeted therapy. They block the protein produced by the BCR-ABL gene that makes white blood cells multiply uncontrollably. These drugs include imatinib (Gleevec), dasatinib (Sprycel) and nilotinib (Tasigna). They’re taken orally. […] Another highly effective option for treating CML is a stem cell or bone marrow transplant (BMT). Typically, the transplant uses stem cells collected from a matched donor, a process called allogeneic transplant. This is a risky procedure, with a treatment-related death rate of 15 to 20%, so it’s only for patients who don’t respond to TKIs. […] Chemotherapy used to be a common treatment for CML. However, TKIs are now known to be more effective, so chemotherapy will be used only if TKIs aren’t working or as part of a stem cell transplant. […] UCSF is dedicated to improving outcomes for patients with CML. Interested patients may have opportunities to participate in clinical trials investigating promising treatments for chronic myeloid leukemia.
  • #1 Chronic Myeloid Leukemia (CML) – Hematology and Oncology – MSD Manual Professional Edition
    https://www.msdmanuals.com/professional/hematology-and-oncology/leukemias/chronic-myeloid-leukemia-cml
    Except when stem cell transplantation is successful, treatment is not proven to be curative. However, tyrosine kinase inhibitors prolong survival. […] Tyrosine kinase inhibitors inhibit the BCR-ABL oncogene, which is responsible for induction of CML. […] The response to TKI therapy is the most important prognostic factor for patients with CML. […] Rarely, other drugs are used as palliation in CML. […] Allogeneic stem cell transplantation, because of its toxicity and because of the efficacy of tyrosine kinase inhibitors, is used selectively. Transplantation is reserved for patients with accelerated- or blast-phase CML resistant to BCR-ABL inhibitors. Transplantation can be curative. […] Tyrosine kinase inhibitors are extremely effective, prolong survival, and may even be curative. […] Stem cell transplantation can be curative and may help patients who do not respond to tyrosine kinase inhibitors or who progress to accelerated or blast phase.
  • #1 Chronic Myelogenous Leukemia (CML) – Information – OHC
    https://ohcare.com/condition/myelogenous-leukemia-chronic-cml/
    Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells without harming normal cells. […] Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. […] Biologic therapy, or immunotherapy, is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer. […] High-dose chemotherapy with stem cell transplant is a method of giving high doses of chemotherapy and replacing blood-forming cells destroyed by the cancer treatment. […] Donor lymphocyte infusion (DLI) is a cancer treatment that may be used after stem cell transplant. […] Splenectomy is surgery to remove the spleen.
  • #1 8 Leukemia Nursing Care Plans – Nurseslabs
    https://nurseslabs.com/leukemia-nursing-care-plans/
    The nursing management and care plan for patients with leukemia involve several important aspects. Nurses play a crucial role in assessing and monitoring patients, managing symptoms, and providing support throughout the treatment journey. […] The following are the nursing priorities for patients with leukemia: Minimizing infection through infection control, Managing side effects of chemotherapy, Managing pain, Providing emotional support, Providing health teachings. […] Clients with leukemia are at risk for infection due to the diseases impact on the bone marrow and immune system. Leukemia disrupts the production of normal blood cells, including white blood cells that play a crucial role in fighting infections, leaving the body vulnerable to bacterial, fungal, and viral infections. […] Infection prevention strategies are essential in reducing the risk of complications and ensuring optimal treatment outcomes.
  • #1 Leukemia Nursing Diagnosis & Care Plan – NurseStudy.Net
    https://nursestudy.net/leukemia-nursing-diagnosis/
    Nursing Care Plan 1. Risk for Infection […] Nursing Diagnosis Statement: Risk for Infection related to compromised immune system secondary to leukemia and chemotherapy effects. […] Nursing Interventions and Rationales: Implement strict infection control protocols. Rationale: Prevents exposure to pathogens in immunocompromised patients. Monitor vital signs every 4 hours. Rationale: Early detection of infection signs. Assess for signs of infection at all potential sites. Rationale: Enables prompt intervention. Educate the patient about neutropenic precautions. Rationale: Empowers patient self-care and infection prevention. […] Desired Outcomes: The patient will remain free from infection. The patient will demonstrate an understanding of infection prevention measures. The patient will maintain a normal temperature range.
  • #1 Leukemia Nursing Care Plan | RNspeak
    https://rnspeak.com/leukemia-nursing-care-plan/
    Chronic Myelogenous Leukemia (CML) is common in adults. This type affects lymphoid cells created in the bone marrow. […] Nursing priorities include preventing infection during acute phases of disease/treatment, maintaining circulating blood volume, alleviating pain, promoting optimal physical functioning, providing psychological support, and providing information about disease process/prognosis and treatment needs. […] Nursing diagnosis: Risk for Infection. Risk factors may include inadequate secondary defenses: alterations in mature WBCs (low granulocyte and abnormal lymphocyte count), increased number of immature lymphocytes; immunosuppression, bone marrow suppression (effects of therapy/transplant). […] Nursing diagnosis: Risk for deficient fluid volume. Risk factors may include excessive losses, e.g., vomiting, hemorrhage, diarrhea; decreased fluid intake, e.g., nausea, anorexia; loss of fluid through abnormal routes, e.g. drains; increased fluid need, e.g., hypermetabolic state, fever; predisposition for kidney stone formation/tumor lysis syndrome; insufficient knowledge regarding the cause and prevention of fluid deficit; medication, e.g. diuretics.
  • #1 Leukemia: Nursing Diagnosis & Interventions | Nurse.com
    https://www.nurse.com/clinical-guides/leukemia/?srsltid=AfmBOor7eSZ9quNCV83cSVmU3UA9LSmkZX8j7n8WN-rRHBqkx87yOQwZ
    Risk for bleeding related to thrombocytopenia and bone marrow suppression […] Fatigue related to anemia and the effects of chemotherapy […] Disturbed body image related to hair loss, weight loss, and pallor from leukemia treatment. […] Infection prevention: Implement neutropenic precautions, such as hand hygiene, limiting visitors, and avoiding exposure to infectious agents. […] Bleeding precautions: Educate the patient on avoiding activities that may lead to injury, using soft toothbrushes, and avoiding over-the-counter medications like aspirin. […] Supportive care: Provide energy-conserving strategies for managing fatigue, such as frequent rest periods and small, nutrient-dense meals. […] Emotional support: Offer counseling services and encourage participation in leukemia support groups. Assist patients with coping strategies and body image issues, including hair loss management.
  • #1 Leukemia: Nursing Diagnosis & Interventions | Nurse.com
    https://www.nurse.com/clinical-guides/leukemia/?srsltid=AfmBOor7eSZ9quNCV83cSVmU3UA9LSmkZX8j7n8WN-rRHBqkx87yOQwZ
    Leukemia patients often experience fatigue, infection risk, bleeding, and emotional distress. Nurses must focus on managing these symptoms and providing education and support throughout the treatment process. […] Monitor CBC and differential: Watch for signs of increased risk for infection (neutropenia), anemia, and thrombocytopenia. […] Evaluate for signs of infection: Fever, chills, and any new symptoms should be reported immediately, as leukemia patients are immunocompromised. […] Assess bleeding: Look for petechiae, bruising, and bleeding gums, particularly in thrombocytopenic patients. […] Psychosocial assessment: Determine the patients coping mechanisms, support system, and need for psychological support. […] Risk for infection related to leukopenia and immunosuppressive treatments
  • #1 Leukemia: Nursing Diagnosis & Interventions | Nurse.com
    https://www.nurse.com/clinical-guides/leukemia/?srsltid=AfmBOor7eSZ9quNCV83cSVmU3UA9LSmkZX8j7n8WN-rRHBqkx87yOQwZ
    Patient will remain free of infection and bleeding complications […] Fatigue will be managed effectively with appropriate interventions […] Patient will demonstrate understanding of leukemia and its treatment, including potential side effects […] Patient will develop coping strategies to manage the emotional and physical challenges of leukemia. […] Educate the patient and family about the importance of infection prevention and how to recognize signs of infection, such as fever. […] Discuss potential side effects of chemotherapy and targeted therapies, including nausea, hair loss, and increased risk of bleeding. […] Provide information about stem cell transplantation, if applicable, including the process and potential complications. […] Encourage caregivers to provide emotional support and help manage the patients day-to-day needs, including transportation to treatments and ensuring medication adherence.
  • #1 Optimizing Patient Care in Chronic Phase Chronic Myelogenous Leukemia: A Multidisciplinary Approach in: Journal of the National Comprehensive Cancer Network Volume 14 Issue suppl_1 (2016)
    https://jnccn.org/view/journals/jnccn/14/suppl_1/article-pS-1.xml?rskey=EaEf2s&result=1&print
    Close monitoring and timely intervention are necessary for patients at risk of developing pleural effusion during dasatinib therapy. Electrolyte abnormalities should be corrected before the start of treatment with nilotinib and should be monitored periodically. […] Poor adherence to imatinib is associated with undesirable clinical outcomes. Nonadherence to imatinib has been identified as the only independent predictor for poor molecular response to imatinib. Therefore, it is important to communicate with patients concerning some of the predictable and potentially treatable adverse effects of TKIs. Careful monitoring and adequate and appropriate management of adverse events improves adherence for most patients. […] In addition to the medical oncologist, other members of the multidisciplinary team also need to communicate key clinical management points to the patient. Nurse practitioners should be able to effectively monitor and manage potential side effects. They should also educate patients about the importance of taking TKIs as prescribed and reporting adverse effects. The involvement of an oncology pharmacist is essential to understand the complete medication profile of an individual patient, discuss potential drug interactions and work with patients to maximize the benefits of TKI therapy.
  • #1 Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients | Leukemia
    https://www.nature.com/articles/s41375-024-02285-9
    Chronic myeloid leukemia (CML) comprises ~15 to 20% of all adult leukemias and the development of oral BCR::ABL1-targeted tyrosine kinase inhibitors (TKIs) has revolutionized management. […] Adherence to treatment and regular monitoring of treatment responses are crucial to achieve long-term survival as specific treatment response milestones map to risk for disease progression. […] The US National Comprehensive Cancer Network and European LeukemiaNet recommend monitoring every 36 months to confirm adherence to therapy and ensure treatment milestones are met and maintained. […] DCB provides excellent sample stability and is a cost-effective home diagnostic. […] Loss of MMR is also the threshold at which TKI therapy is typically restarted in patients who have discontinued therapy, an intervention that can mitigate chronic side effects, prevent long-term toxicities, improve quality of life, and limit costs to patients and health care systems. […] Given the effectiveness of CML therapy, enhanced monitoring access could be a lifesaving intervention.
  • #1 Chronic myelogenous leukemia // Middlesex Health
    https://middlesexhealth.org/learning-center/diseases-and-conditions/chronic-myelogenous-leukemia
    A bone marrow transplant, also called a stem cell transplant, is the only treatment that can cure chronic myelogenous leukemia. However, it’s usually reserved for people who haven’t been helped by other treatments. […] No alternative medicines have been found to treat chronic myelogenous leukemia. But alternative medicine may help you cope with fatigue, which is common in people with chronic myelogenous leukemia. […] For many people, chronic myelogenous leukemia is a disease they will live with for years. Many will continue treatment with targeted therapy indefinitely. […] Talk to your health care provider about your side effects. Powerful cancer medicines can cause many side effects. Those side effects often can be managed with other medicines or treatments. You don’t have to handle them without help.
  • #1 Chronic myelogenous leukemia – Diagnosis and treatment – Mayo Clinic
    https://www.mayoclinic.org/diseases-conditions/chronic-myelogenous-leukemia/diagnosis-treatment/drc-20352422
    Powerful cancer medicines can cause many side effects. Those side effects often can be managed with other medicines or treatments. You don’t have to handle them without help. […] If you develop side effects, such as skin rashes or fatigue, don’t quit your medicines without talking to your health care provider. […] Having a chronic condition can be emotionally overwhelming. Tell your provider about your feelings. Ask for a referral to a counselor or another specialist with whom you can talk. […] Learn enough about chronic myelogenous leukemia to make decisions about your care. […] Your health care provider is likely to ask you a number of questions. Being ready to answer them may allow time later to cover other points you want to address.
  • #1 Chronic myelogenous leukemia // Middlesex Health
    https://middlesexhealth.org/learning-center/diseases-and-conditions/chronic-myelogenous-leukemia
    If you develop side effects, such as skin rashes or fatigue, don’t quit your medicines without talking to your health care provider. […] Having a chronic condition can be emotionally overwhelming. Tell your provider about your feelings. Ask for a referral to a counselor or another specialist with whom you can talk.
  • #1 Chronic myeloid leukaemia (CML) | Macmillan Cancer Support
    https://www.macmillan.org.uk/cancer-information-and-support/leukaemia/chronic-myeloid-leukaemia-cml
    These test results help your doctors know how well the treatment is working to control the leukaemia. They will also check for any side effects. They can make any changes if needed. […] Most people with CML live a normal lifespan. To help you stay as well as possible, you may want to make changes to your lifestyle. […] Understanding more about CML and its treatment can also help you cope. This means you can discuss treatment, tests and check-ups with your doctors and nurses. It also means you can be involved in making decisions. This can make you feel more confident and more in control. […] Talking about your feelings can help reduce stress, anxiety and isolation. Self-help or support groups offer a chance to talk to other people who may be in a similar situation and facing the same challenges as you.
  • #1 Chronic myelogenous leukemia // Middlesex Health
    https://middlesexhealth.org/learning-center/diseases-and-conditions/chronic-myelogenous-leukemia
    Chronic myelogenous leukemia, also called CML, is an uncommon type of cancer of the bone marrow. […] Advances in treatment have improved the prognosis of people with chronic myelogenous leukemia. Most people can achieve remission and live for many years after diagnosis. […] The goal of chronic myelogenous leukemia treatment is to eliminate the blood cells that contain the BCR-ABL gene. For most people, treatment begins with targeted therapy that may help achieve a long-term remission of the disease. […] Targeted therapy uses medicines that attack specific chemicals in the cancer cells. By blocking these chemicals, targeted therapy can cause cancer cells to die. In chronic myelogenous leukemia, the target of these medicines is the tyrosine kinase protein produced by the BCR-ABL gene. The medicines are called tyrosine kinase inhibitors, also known as TKIs.
  • #1 How We Treat Chronic Myelogenous Leukemia | Dana-Farber Cancer Institute
    https://www.dana-farber.org/cancer-care/types/chronic-myelogenous-leukemia/treatment
    Treatment has several goals. The first is the restoration of your blood counts to normal (hematologic response). […] A distinguishing area of our expertise is evaluating how well you respond to therapy on a molecular level through sensitive testing. […] Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells without harming normal cells. […] Most of the time, patients respond well to TKIs. […] Allogeneic stem cell transplant may be considered if the disease stops responding to TKI treatment. […] Chemotherapy may be considered if targeted therapy and a stem cell transplant are not effective. […] In some cases, CML may become resistant to treatment. […] You will be assigned to one of our leukemia physicians as your primary oncologist overseeing all aspects of your care, both inpatient and outpatient.
  • #1 Home – Chronic myelogenous leukemia – Cancer Institute | Northwell Health
    https://cancer.northwell.edu/cancer-care/chronic-myelogenous-leukemia-cml
    With nationally recognized physicians and the most advanced treatments, Northwell Health is a premier destination for blood cancer care. […] Our hematologic specialists work as a team to deliver coordinated, personalized care for each patient with chronic myelogenous leukemia. […] We offer advanced diagnostic tools and innovative therapies with physicians who specialize in hematologic malignancies. […] Youre not aloneour cancer navigators are here to help facilitate your treatment through every step of your care. […] Since 2002, life expectancy in people with CML has increased dramatically. Today, well over 90% of patients have long-term remissions. At the Northwell Health Cancer Institute, we do everything in our power to ensure you have the best possible outcome.
  • #1 Patient Empowerment in the Management of Chronic Myeloid Leukemia | Oncology Nursing Society
    https://www.ons.org/publications-research/cjon/18/2/patient-empowerment-management-chronic-myeloid-leukemia
    Patient empowerment is a patient-centered approach to care in which healthcare providers nurture patients’ innate abilities to self-manage and incorporate patient goals for therapy into the overall management plan. Standard care of chronic myeloid leukemia (CML) requires lifelong medication with oral therapy and regular follow-up. […] The success of CML treatment, therefore, depends on a high degree of patient involvement and motivation, as well as strong collaboration between patients and healthcare providers. Oncology nurses can support patients with CML from the time of diagnosis to the end of treatment to ensure they maintain high levels of involvement in their care. […] In the current article, the author discusses the potential effect of patient response to cancer diagnosis on clinical outlook and describes strategies in place at the cancer center to ensure that patients diagnosed with CML have the best chance at keeping their cancer under control.
  • #1 Treatment Planning | Stanford Health Care
    https://stanfordhealthcare.org/medical-conditions/cancer/chronic-myeloid-leukemia/patient-care-resources/treatment-planning.html
    Your care team will recommend treatment options based on your specific diagnosis. Different types of treatment for leukemia have different goals, such as: Slowing or stopping the growth of cancer; Destroying cancer cells; Delaying or preventing cancer from coming back (recurrence); Managing symptoms of incurable cancer. […] Your care team can help you understand how various treatments can help you achieve your goals. Discuss what you want to be able to do, both during treatment and after it is complete. […] Your health care team for leukemia brings together a multispecialty team of experts dedicated to treating leukemia, blood cancer, and rare forms of blood disorders. […] Multidisciplinary care coordinators are specialized registered nurses who provide one-on-one support to guide you through the cancer treatment process. These coordinators serve as your point of contact to help manage your care, from your first appointment through follow-up visits. They assess your needs, answer your questions, make referrals, coordinate appointments, and provide patient education.
  • #2 Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients | Leukemia
    https://www.nature.com/articles/s41375-024-02285-9
    Chronic myeloid leukemia (CML) comprises ~15 to 20% of all adult leukemias and the development of oral BCR::ABL1-targeted tyrosine kinase inhibitors (TKIs) has revolutionized management. […] Adherence to treatment and regular monitoring of treatment responses are crucial to achieve long-term survival as specific treatment response milestones map to risk for disease progression. […] The US National Comprehensive Cancer Network and European LeukemiaNet recommend monitoring every 36 months to confirm adherence to therapy and ensure treatment milestones are met and maintained. […] DCB provides excellent sample stability and is a cost-effective home diagnostic. […] Loss of MMR is also the threshold at which TKI therapy is typically restarted in patients who have discontinued therapy, an intervention that can mitigate chronic side effects, prevent long-term toxicities, improve quality of life, and limit costs to patients and health care systems. […] Given the effectiveness of CML therapy, enhanced monitoring access could be a lifesaving intervention.
  • #2 Chronic Myeloid Leukemia (CML) | Learn What Is CML | LLS
    https://www.lls.org/leukemia/chronic-myeloid-leukemia
    Chronic myeloid leukemia (CML) is also called chronic myelogenous leukemia, chronic granulocytic leukemia and chronic myelocytic leukemia. CML is one of four main types of leukemia. […] Most CML patients are treated with daily oral drug therapy. […] Since the introduction of tyrosine kinase inhibitor (TKI) therapy in 2001, CML has been transformed from a life-threatening disease to a manageable chronic condition for most patients. People are living longer with CML and experiencing fewer treatment side effects. […] Make sure your doctor continually monitors your response to medication, which is essential to bringing your CML under control. […] CML doesn’t completely interfere with the development of mature red cells, white cells and platelets. Therefore, chronic phase CML is generally less severe than acute leukemia. […] All cases of CML are caused by the BCR::ABL1 fusion gene. This gene is not found in normal blood cells. […] For most people who have chronic myeloid leukemia (CML), there are no obvious reasons why they develop the disease.
  • #2 Chronic Myeloid Leukemia (CML) | Signs and Symptoms of CML | LLS
    https://www.lls.org/leukemia/chronic-myeloid-leukemia/signs-and-symptoms
    People who have chronic myeloid leukemia (CML) may not have any symptoms at first. Often, patients learn they have CML after a routine physical exam or a blood test. CML signs and symptoms tend to develop gradually. Those with symptoms often report experiencing: […] Many signs and symptoms of CML occur because the CML cells crowd out the bone marrows healthy red blood cells, white blood cells and platelets. […] Anemia is a lack of red blood cells that can cause weakness, fatigue and shortness of breath. A lack of normal white blood cells can increase the risk of infection, and a lack of platelets can lead to excessive bruising or bleeding. Symptoms may also occur because CML cells accumulate in organs such as the spleen. Some patients may have a high platelet count.
  • #2 Leukemia: Nursing Diagnoses, Care Plans, Assessment & Interventions | NurseTogether
    https://www.nursetogether.com/leukemia-nursing-diagnosis-care-plan/
    Leukemia is classified according to the rate at which the condition progresses and whether the leukemia cells come from lymphoid or myeloid cells. […] Chronic Myelogenous Leukemia (CML) occurs mainly in adults. It frequently does not show symptoms early on, but the patient may exhibit night sweats, frequent infections, weight loss, fatigue, and fever later on. […] Nurses support patients with leukemia by providing supportive care, especially for those who are undergoing chemotherapy, radiation, and other biologic therapies. It is essential to manage and prevent complications, provide comfort measures, patient and family education, and continuous emotional support. […] Nursing interventions and care are essential for the patients recovery. […] Administer growth factors as ordered. Administer growth factors as ordered before harvesting stem cells for a stem cell transplant. Growth factors stimulate the development of new blood cells in the bone marrow. Granulocyte colony-stimulating factor stimulates the production of WBCs, erythropoietin stimulates new RBCs, and thrombopoietin stimulates platelet growth.
  • #2 Chronic Myelogenous Leukemia | Oncology Nursing Society
    https://www.ons.org/publications-research/cjon/9/5/chronic-myelogenous-leukemia
    Chronic myelogenous leukemia (CML) represents about 14% of all leukemias and occurs with a frequency of about 1 in 100,000. […] Symptoms include fatigue, weight loss, sweating, and abdominal discomfort from an enlarged spleen. […] Most patients are diagnosed during the chronic phase. […] Imatinib mesylate, a tyrosine kinase inhibitor, was approved in 2002 for the treatment of all phases of CML. […] Because of its effectiveness, imatinib has become the treatment of choice for most patients with CML. […] Stem cell transplantation also is an option for eligible patients. […] Oncology nurses who are knowledgeable about new therapies for CML can be effective resources for their patients.
  • #2 Chronic Myelogenous Leukemia | NYU Langone Health
    https://nyulangone.org/conditions/chronic-myelogenous-leukemia
    We conduct sophisticated diagnostic tests such as chromosomal analysis to identify chronic myelogenous leukemia, a slow-growing cancer of the bone marrow and blood. […] We offer targeted chemotherapy that helps some people achieve long-term remission, in which cancer cells are no longer detected in the body. […] Stem cell transplantation is available for more aggressive cancer. […] We also provide psychosocial support to help you thrive during treatment for this chronic condition.
  • #2 Leukemia: What Primary Care Physicians Need to Know | AAFP
    https://www.aafp.org/pubs/afp/issues/2023/0400/leukemia.html
    Asymptomatic, early-stage chronic lymphocytic leukemia (i.e., absence of anemia and thrombocytopenia and less than three areas of lymph node involvement) may be monitored without treatment. Progression to active-stage disease is defined by worsening constitutional symptoms, lymphocytosis, thrombocytopenia, anemia, progressive lymphadenopathy, or hepatosplenomegaly and requires treatment. […] Hyperleukocytosis (more than 100,000 per L [100 109 per L] white blood cells) is a hallmark of chronic myelogenous and chronic lymphocytic leukemia. A peripheral blood smear should be obtained if hyperleukocytosis is present on complete blood count, especially when associated with anemia, thrombocytopenia, thrombocytosis, hepatosplenomegaly, lymphadenopathy, or unexplained constitutional symptoms. […] The diagnosis of chronic lymphocytic leukemia requires at least 5,000 per L (5 109 per L) monoclonal B lymphocytes on a peripheral blood smear and should be confirmed with flow cytometry. Chronic myelogenous leukemia is characterized by identification of the Philadelphia chromosome through cytogenic or molecular testing of bone marrow or peripheral blood smear.
  • #2 Chronic Myelogenous Leukemia – CML | Hematology-Oncology Associates of CNY
    https://www.hoacny.com/our-services/cancers-we-treat/chronic-myelogenous-leukemia-cml
    Treatment of blastic phase chronic myeloid leukemia may include: targeted therapy (imatinib mesylate, dasatinib, nilotinib, bosutinib), allogeneic bone marrow transplant or stem cell transplant, and chemotherapy as palliative therapy to relieve symptoms and improve quality of life. […] In relapsed chronic myeloid leukemia (CML), the number of blast cells increases after a remission. Treatment of relapsed CML may include targeted therapy (ponatinib or asciminib).
  • #2 Chronic myelogenous leukemia // Middlesex Health
    https://middlesexhealth.org/learning-center/diseases-and-conditions/chronic-myelogenous-leukemia
    Chronic myelogenous leukemia, also called CML, is an uncommon type of cancer of the bone marrow. […] Advances in treatment have improved the prognosis of people with chronic myelogenous leukemia. Most people can achieve remission and live for many years after diagnosis. […] The goal of chronic myelogenous leukemia treatment is to eliminate the blood cells that contain the BCR-ABL gene. For most people, treatment begins with targeted therapy that may help achieve a long-term remission of the disease. […] Targeted therapy uses medicines that attack specific chemicals in the cancer cells. By blocking these chemicals, targeted therapy can cause cancer cells to die. In chronic myelogenous leukemia, the target of these medicines is the tyrosine kinase protein produced by the BCR-ABL gene. The medicines are called tyrosine kinase inhibitors, also known as TKIs.
  • #2 Chronic Myeloid Leukemia (CML): Symptoms, Treatment & Prognosis
    https://my.clevelandclinic.org/health/diseases/21845-chronic-myelogenous-leukemia-cml
    Chronic myeloid leukemia (CML) is blood cancer that starts in the blood-forming myeloid cells or stem cells in your bone marrow. Healthcare providers treat CML with innovative therapies that have turned CML from being a potentially life-threatening illness into a chronic illness. […] Healthcare providers typically treat chronic phase CML with tyrosine kinase inhibitors (TKIs). TKIs are a type of targeted therapy. In CML, the targets are the abnormal BCR-ABL enzymes that let abnormal white blood cells divide and multiply uncontrollably. TKIs block the enzymes so that CML cells start to die. […] If you have chronic myeloid leukemia, you may need to take medication for the rest of your life. You’ll also need regular checkups so your healthcare provider can monitor your overall health. They’ll look for signs that CML has come back and for signs of second cancers. […] At Cleveland Clinic, you can get the latest treatments and compassionate care for chronic myelogenous leukemia (CML).
  • #2 Chronic Myelogenous Leukemia – CML | Hematology-Oncology Associates of CNY
    https://www.hoacny.com/our-services/cancers-we-treat/chronic-myelogenous-leukemia-cml
    Chronic myeloid leukemia is a disease in which the bone marrow makes too many white blood cells. […] Signs and symptoms of chronic myeloid leukemia include weight loss and tiredness. […] Tests that examine the blood and bone marrow are used to diagnose chronic myeloid leukemia. […] Certain factors affect prognosis (chance of recovery) and treatment options. […] There are different types of treatment for patients with chronic myeloid leukemia. […] Treatment for chronic myeloid leukemia may cause side effects. […] Follow-up care may be needed. […] Treatment of chronic phase chronic myeloid leukemia may include: targeted therapy (asciminib, imatinib mesylate, nilotinib, dasatinib, bosutinib) and allogeneic bone marrow transplant or stem cell transplant. […] Treatment of accelerated phase chronic myeloid leukemia may include: targeted therapy (bosutinib) and targeted therapy (imatinib mesylate) followed by allogeneic stem cell transplant.
  • #2 Chronic Myeloid Leukemia (CML) – Hematology and Oncology – MSD Manual Professional Edition
    https://www.msdmanuals.com/professional/hematology-and-oncology/leukemias/chronic-myeloid-leukemia-cml
    Chronic myeloid leukemia (CML) occurs when a pluripotent stem cell undergoes malignant transformation and clonal myeloproliferation, leading to a striking overproduction of mature and immature granulocytes. […] Treatment is with tyrosine kinase inhibitors (TKI) such as imatinib, dasatinib, nilotinib, bosutinib, and ponatinib, which significantly improve response and prolong survival. Myelosuppressive drugs (eg, hydroxyurea), stem cell transplantation, and interferon alfa are also sometimes used. […] Treatment of chronic myeloid leukemia depends on the stage of disease. In the asymptomatic chronic phase, tyrosine kinase inhibitors (eg, imatinib, nilotinib, dasatinib, bosutinib, ponatinib) are the initial treatment choice; they are not curative but are extremely effective. […] Allogeneic hematopoietic stem cell transplantation is reserved for patients with accelerated or blast phase CML or those with disease resistant to the available tyrosine kinase inhibitors.
  • #2 Chronic myelogenous leukemia | Beacon Health System
    https://www.beaconhealthsystem.org/library/diseases-and-conditions/chronic-myelogenous-leukemia?content_id=CON-20167627
    Chronic myelogenous leukemia Comprehensive overview covers diagnosis, treatment of CML. […] The goal of chronic myelogenous leukemia treatment is to eliminate the blood cells that contain the BCR-ABL gene. For most people, treatment begins with targeted therapy that may help achieve a long-term remission of the disease. […] Targeted therapy uses medicines that attack specific chemicals in the cancer cells. By blocking these chemicals, targeted therapy can cause cancer cells to die. In chronic myelogenous leukemia, the target of these medicines is the tyrosine kinase protein produced by the BCR-ABL gene. The medicines are called tyrosine kinase inhibitors, also known as TKIs. […] TKIs are the initial treatment for people diagnosed with chronic myelogenous leukemia. Side effects of these targeted medicines include swelling or puffiness of the skin, nausea, muscle cramps, fatigue, diarrhea, and skin rashes.
  • #2 Chronic myelogenous leukemia | Beacon Health System
    https://www.beaconhealthsystem.org/library/diseases-and-conditions/chronic-myelogenous-leukemia?content_id=CON-20167627
    Blood tests to detect the presence of the BCR-ABL gene are used to monitor the effectiveness of targeted therapy. If the disease doesn’t respond or becomes resistant to targeted therapy, health care providers may consider other targeted therapy medicines or other treatments. […] A bone marrow transplant, also called a stem cell transplant, is the only treatment that can cure chronic myelogenous leukemia. However, it’s usually reserved for people who haven’t been helped by other treatments. […] Chemotherapy uses strong medicines to kill cancer cells. Chemotherapy medicines are sometimes combined with targeted therapy to treat aggressive chronic myelogenous leukemia. […] No alternative medicines have been found to treat chronic myelogenous leukemia. But alternative medicine may help you cope with fatigue, which is common in people with chronic myelogenous leukemia.
  • #2 Chronic myeloid leukemia | Conditions | UCSF Health
    https://www.ucsfhealth.org/conditions/chronic-myeloid-leukemia
    Tyrosine kinase inhibitors (TKIs) are drugs used for targeted therapy. They block the protein produced by the BCR-ABL gene that makes white blood cells multiply uncontrollably. These drugs include imatinib (Gleevec), dasatinib (Sprycel) and nilotinib (Tasigna). They’re taken orally. […] Another highly effective option for treating CML is a stem cell or bone marrow transplant (BMT). Typically, the transplant uses stem cells collected from a matched donor, a process called allogeneic transplant. This is a risky procedure, with a treatment-related death rate of 15 to 20%, so it’s only for patients who don’t respond to TKIs. […] Chemotherapy used to be a common treatment for CML. However, TKIs are now known to be more effective, so chemotherapy will be used only if TKIs aren’t working or as part of a stem cell transplant. […] UCSF is dedicated to improving outcomes for patients with CML. Interested patients may have opportunities to participate in clinical trials investigating promising treatments for chronic myeloid leukemia.
  • #2 8 Leukemia Nursing Care Plans – Nurseslabs
    https://nurseslabs.com/leukemia-nursing-care-plans/
    The nursing management and care plan for patients with leukemia involve several important aspects. Nurses play a crucial role in assessing and monitoring patients, managing symptoms, and providing support throughout the treatment journey. […] The following are the nursing priorities for patients with leukemia: Minimizing infection through infection control, Managing side effects of chemotherapy, Managing pain, Providing emotional support, Providing health teachings. […] Clients with leukemia are at risk for infection due to the diseases impact on the bone marrow and immune system. Leukemia disrupts the production of normal blood cells, including white blood cells that play a crucial role in fighting infections, leaving the body vulnerable to bacterial, fungal, and viral infections. […] Infection prevention strategies are essential in reducing the risk of complications and ensuring optimal treatment outcomes.
  • #2 Leukemia Nursing Care Plan | RNspeak
    https://rnspeak.com/leukemia-nursing-care-plan/
    Chronic Myelogenous Leukemia (CML) is common in adults. This type affects lymphoid cells created in the bone marrow. […] Nursing priorities include preventing infection during acute phases of disease/treatment, maintaining circulating blood volume, alleviating pain, promoting optimal physical functioning, providing psychological support, and providing information about disease process/prognosis and treatment needs. […] Nursing diagnosis: Risk for Infection. Risk factors may include inadequate secondary defenses: alterations in mature WBCs (low granulocyte and abnormal lymphocyte count), increased number of immature lymphocytes; immunosuppression, bone marrow suppression (effects of therapy/transplant). […] Nursing diagnosis: Risk for deficient fluid volume. Risk factors may include excessive losses, e.g., vomiting, hemorrhage, diarrhea; decreased fluid intake, e.g., nausea, anorexia; loss of fluid through abnormal routes, e.g. drains; increased fluid need, e.g., hypermetabolic state, fever; predisposition for kidney stone formation/tumor lysis syndrome; insufficient knowledge regarding the cause and prevention of fluid deficit; medication, e.g. diuretics.
  • #2 Leukemia: Nursing Diagnosis & Interventions | Nurse.com
    https://www.nurse.com/clinical-guides/leukemia/?srsltid=AfmBOor7eSZ9quNCV83cSVmU3UA9LSmkZX8j7n8WN-rRHBqkx87yOQwZ
    Leukemia patients often experience fatigue, infection risk, bleeding, and emotional distress. Nurses must focus on managing these symptoms and providing education and support throughout the treatment process. […] Monitor CBC and differential: Watch for signs of increased risk for infection (neutropenia), anemia, and thrombocytopenia. […] Evaluate for signs of infection: Fever, chills, and any new symptoms should be reported immediately, as leukemia patients are immunocompromised. […] Assess bleeding: Look for petechiae, bruising, and bleeding gums, particularly in thrombocytopenic patients. […] Psychosocial assessment: Determine the patients coping mechanisms, support system, and need for psychological support. […] Risk for infection related to leukopenia and immunosuppressive treatments
  • #2 Leukemia: Nursing Diagnosis & Interventions | Nurse.com
    https://www.nurse.com/clinical-guides/leukemia/?srsltid=AfmBOor7eSZ9quNCV83cSVmU3UA9LSmkZX8j7n8WN-rRHBqkx87yOQwZ
    Risk for bleeding related to thrombocytopenia and bone marrow suppression […] Fatigue related to anemia and the effects of chemotherapy […] Disturbed body image related to hair loss, weight loss, and pallor from leukemia treatment. […] Infection prevention: Implement neutropenic precautions, such as hand hygiene, limiting visitors, and avoiding exposure to infectious agents. […] Bleeding precautions: Educate the patient on avoiding activities that may lead to injury, using soft toothbrushes, and avoiding over-the-counter medications like aspirin. […] Supportive care: Provide energy-conserving strategies for managing fatigue, such as frequent rest periods and small, nutrient-dense meals. […] Emotional support: Offer counseling services and encourage participation in leukemia support groups. Assist patients with coping strategies and body image issues, including hair loss management.
  • #2 Leukemia Nursing Care Plan | RNspeak
    https://rnspeak.com/leukemia-nursing-care-plan/
    Nursing diagnosis: Acute pain. Physical agents, e.g. enlarged organs/lymph nodes, bone marrow packed with leukemic cells; chemical agents, e.g. antileukemic treatments; psychological manifestations, e.g. anxiety, fear. […] Nursing diagnosis: Activity intolerance. May be related to generalized weakness; reduced energy stores, increased metabolic rate from massive production of leukocytes; sedentary lifestyle; bedrest/immobility; imbalance between oxygen supply and demand (anemia/hypoxia); therapeutic restrictions (isolation/bedrest); effect of drug therapy. […] Nursing Diagnosis: Knowledge Deficit regarding disease, prognosis, treatment, self-care, and discharge needs. May be related to lack of exposure to resources, information misinterpretation/lack of recall, information misinterpretation, unfamiliarity with information resources, cognitive limitation, lack of interest in learning.
  • #2 Leukemia Nursing Diagnosis & Care Plan – NurseStudy.Net
    https://nursestudy.net/leukemia-nursing-diagnosis/
    Nursing Care Plan 1. Risk for Infection […] Nursing Diagnosis Statement: Risk for Infection related to compromised immune system secondary to leukemia and chemotherapy effects. […] Nursing Interventions and Rationales: Implement strict infection control protocols. Rationale: Prevents exposure to pathogens in immunocompromised patients. Monitor vital signs every 4 hours. Rationale: Early detection of infection signs. Assess for signs of infection at all potential sites. Rationale: Enables prompt intervention. Educate the patient about neutropenic precautions. Rationale: Empowers patient self-care and infection prevention. […] Desired Outcomes: The patient will remain free from infection. The patient will demonstrate an understanding of infection prevention measures. The patient will maintain a normal temperature range.
  • #2 Chronic myeloid leukaemia (CML) | Macmillan Cancer Support
    https://www.macmillan.org.uk/cancer-information-and-support/leukaemia/chronic-myeloid-leukaemia-cml
    These test results help your doctors know how well the treatment is working to control the leukaemia. They will also check for any side effects. They can make any changes if needed. […] Most people with CML live a normal lifespan. To help you stay as well as possible, you may want to make changes to your lifestyle. […] Understanding more about CML and its treatment can also help you cope. This means you can discuss treatment, tests and check-ups with your doctors and nurses. It also means you can be involved in making decisions. This can make you feel more confident and more in control. […] Talking about your feelings can help reduce stress, anxiety and isolation. Self-help or support groups offer a chance to talk to other people who may be in a similar situation and facing the same challenges as you.
  • #2
    https://myhealth.alberta.ca/Health/aftercareinformation/pages/conditions.aspx?hwid=uf8178
    Leukemia is a type of cancer that causes your body to make too many blood cells, especially white blood cells. […] In chronic myeloid leukemia (CML), some of the young white blood cells don’t mature like they should. […] There are many treatments for CML, including targeted therapy with tyrosine kinase inhibitors, chemotherapy, and stem cell transplants. A healthy diet, exercise, extra rest, and a strong support system can help you feel better. […] Follow-up care is a key part of your treatment and safety. Be sure to make and go to all appointments, and call your doctor or nurse advice line if you are having problems. […] Take your medicines exactly as prescribed. […] Eat healthy food. If you do not feel like eating, try to eat food that has protein and extra calories to keep up your strength and prevent weight loss.
  • #2 Chronic myelogenous leukemia | Beacon Health System
    https://www.beaconhealthsystem.org/library/diseases-and-conditions/chronic-myelogenous-leukemia?content_id=CON-20167627
    For many people, chronic myelogenous leukemia is a disease they will live with for years. Many will continue treatment with targeted therapy indefinitely. […] Talk to your health care provider about your side effects. Powerful cancer medicines can cause many side effects. Those side effects often can be managed with other medicines or treatments. You don’t have to handle them without help. […] If you develop side effects, such as skin rashes or fatigue, don’t quit your medicines without talking to your health care provider. […] Having a chronic condition can be emotionally overwhelming. Tell your provider about your feelings. Ask for a referral to a counselor or another specialist with whom you can talk.
  • #2 Chronic myelogenous leukemia // Middlesex Health
    https://middlesexhealth.org/learning-center/diseases-and-conditions/chronic-myelogenous-leukemia
    If you develop side effects, such as skin rashes or fatigue, don’t quit your medicines without talking to your health care provider. […] Having a chronic condition can be emotionally overwhelming. Tell your provider about your feelings. Ask for a referral to a counselor or another specialist with whom you can talk.
  • #2 Chronic Myelogenous Leukemia, Blood Cancer, Information, Resources
    https://www.cancercare.org/diagnosis/chronic_myelogenous_leukemia
    Cancer Care provides free, professional support services for people affected by chronic myelogenous leukemia, as well as treatment information and additional resources. […] Oncology social workers help you cope with the emotional and practical challenges of chronic myelogenous leukemia. […] Find resources and support to manage your financial concerns. Limited assistance from Cancer Care is available to eligible families for cancer-related costs. […] Connect with others in our free support groups led by oncology social workers. […] Cancer Care offers specialized programs to address specific populations and concerns. […] Read or order our free Connect booklets and fact sheets offering easy-to-read information about the latest cancer treatments, managing side effects and coping with cancer. […] Treatment Update: Chronic Myelogenous Leukemia. […] We currently don’t have any Ask Cancer Care Q&As specifically about chronic myelogenous leukemia.
  • #2 Chronic myelogenous leukemia | Health Library | Memorial Health System
    https://www.mhsystem.org/health-library/con-20167627/
    Chronic myelogenous leukemia, also called CML, is an uncommon type of cancer of the bone marrow. […] Advances in treatment have improved the prognosis of people with chronic myelogenous leukemia. Most people can achieve remission and live for many years after diagnosis. […] The goal of chronic myelogenous leukemia treatment is to eliminate the blood cells that contain the BCR-ABL gene. For most people, treatment begins with targeted therapy that may help achieve a long-term remission of the disease. […] Targeted therapy uses medicines that attack specific chemicals in the cancer cells. By blocking these chemicals, targeted therapy can cause cancer cells to die. In chronic myelogenous leukemia, the target of these medicines is the tyrosine kinase protein produced by the BCR-ABL gene. The medicines are called tyrosine kinase inhibitors, also known as TKIs.
  • #2 Treatment Planning | Stanford Health Care
    https://stanfordhealthcare.org/medical-conditions/cancer/chronic-myeloid-leukemia/patient-care-resources/treatment-planning.html
    Your care team will recommend treatment options based on your specific diagnosis. Different types of treatment for leukemia have different goals, such as: Slowing or stopping the growth of cancer; Destroying cancer cells; Delaying or preventing cancer from coming back (recurrence); Managing symptoms of incurable cancer. […] Your care team can help you understand how various treatments can help you achieve your goals. Discuss what you want to be able to do, both during treatment and after it is complete. […] Your health care team for leukemia brings together a multispecialty team of experts dedicated to treating leukemia, blood cancer, and rare forms of blood disorders. […] Multidisciplinary care coordinators are specialized registered nurses who provide one-on-one support to guide you through the cancer treatment process. These coordinators serve as your point of contact to help manage your care, from your first appointment through follow-up visits. They assess your needs, answer your questions, make referrals, coordinate appointments, and provide patient education.
  • #3 Chronic Myeloid Leukemia (CML) – Hematology and Oncology – MSD Manual Professional Edition
    https://www.msdmanuals.com/professional/hematology-and-oncology/leukemias/chronic-myeloid-leukemia-cml
    Chronic myeloid leukemia (CML) occurs when a pluripotent stem cell undergoes malignant transformation and clonal myeloproliferation, leading to a striking overproduction of mature and immature granulocytes. […] Treatment is with tyrosine kinase inhibitors (TKI) such as imatinib, dasatinib, nilotinib, bosutinib, and ponatinib, which significantly improve response and prolong survival. Myelosuppressive drugs (eg, hydroxyurea), stem cell transplantation, and interferon alfa are also sometimes used. […] Treatment of chronic myeloid leukemia depends on the stage of disease. In the asymptomatic chronic phase, tyrosine kinase inhibitors (eg, imatinib, nilotinib, dasatinib, bosutinib, ponatinib) are the initial treatment choice; they are not curative but are extremely effective. […] Allogeneic hematopoietic stem cell transplantation is reserved for patients with accelerated or blast phase CML or those with disease resistant to the available tyrosine kinase inhibitors.
  • #3 Types of Leukemia: Common, Rare & More
    https://www.cancercenter.com/cancer-types/leukemia/types
    Chronic myeloid leukemia, also known as chronic myelogenous leukemia, begins in the blood-forming cells of the bone marrow and then, over time, spreads to the blood. […] CML is slow-growing, but once it starts causing symptoms, these may include fatigue, fever, weight loss and an enlarged spleen. Around half of CML cases are diagnosed by a blood test before symptoms have begun. […] Treatment options include: Targeted therapy, Chemotherapy, Immunotherapy, Stem cell transplant. […] Your multidisciplinary team will work with you to develop a personalized plan to treat your leukemia in a way that fits your individual needs and goals.
  • #3 8 Leukemia Nursing Care Plans – Nurseslabs
    https://nurseslabs.com/leukemia-nursing-care-plans/
    Therapeutic interventions and nursing actions for patients with leukemia may include: Promoting Infection Control and Management, Managing Fluid Volume, Managing Acute Pain, Enhancing Tolerance to Activity, Initiating Health Teachings and Patient Education, Assessing and Monitoring for Potential Complications, Administering Medications and Pharmacologic Support, Monitoring Laboratory and Diagnostic Procedures. […] Administering medications and providing pharmacologic support are essential components of the comprehensive care provided to patients with leukemia. Nurses play a crucial role in administering medications, monitoring their effectiveness and side effects, and providing education and support to patients and their families. […] By promptly recognizing and reporting these potential complications, nurses enable the healthcare team to initiate appropriate interventions, such as administering antibiotics, managing pain, providing transfusions, or adjusting treatment regimens.
  • #3 Leukemia Nursing Diagnosis & Care Plan – NurseStudy.Net
    https://nursestudy.net/leukemia-nursing-diagnosis/
    Nursing Care Plan 3. Risk for Bleeding […] Nursing Diagnosis Statement: Risk for Bleeding related to thrombocytopenia secondary to leukemia and treatment effects. […] Nursing Interventions and Rationales: Monitor platelet counts and coagulation studies. Rationale: Identifies bleeding risk level. Implement bleeding precautions. Rationale: Prevents trauma and bleeding. Assess for signs of bleeding. Rationale: Enables early intervention. Administer blood products as ordered. Rationale: Maintains adequate platelet levels. […] Desired Outcomes: The patient will remain free from bleeding episodes. Patient will demonstrate an understanding of bleeding precautions. The patient will maintain stable hemoglobin and platelet levels. […] Nursing Care Plan 4. Impaired Oral Mucous Membrane […] Nursing Diagnosis Statement: Impaired Oral Mucous Membrane related to chemotherapy effects as evidenced by oral pain and mucositis.
  • #3 Leukemia Nursing Diagnosis & Care Plan – NurseStudy.Net
    https://nursestudy.net/leukemia-nursing-diagnosis/
    Nursing Care Plan 1. Risk for Infection […] Nursing Diagnosis Statement: Risk for Infection related to compromised immune system secondary to leukemia and chemotherapy effects. […] Nursing Interventions and Rationales: Implement strict infection control protocols. Rationale: Prevents exposure to pathogens in immunocompromised patients. Monitor vital signs every 4 hours. Rationale: Early detection of infection signs. Assess for signs of infection at all potential sites. Rationale: Enables prompt intervention. Educate the patient about neutropenic precautions. Rationale: Empowers patient self-care and infection prevention. […] Desired Outcomes: The patient will remain free from infection. The patient will demonstrate an understanding of infection prevention measures. The patient will maintain a normal temperature range.
  • #4 Leukemia Nursing Diagnosis & Care Plan – NurseStudy.Net
    https://nursestudy.net/leukemia-nursing-diagnosis/
    Nursing Care Plan 3. Risk for Bleeding […] Nursing Diagnosis Statement: Risk for Bleeding related to thrombocytopenia secondary to leukemia and treatment effects. […] Nursing Interventions and Rationales: Monitor platelet counts and coagulation studies. Rationale: Identifies bleeding risk level. Implement bleeding precautions. Rationale: Prevents trauma and bleeding. Assess for signs of bleeding. Rationale: Enables early intervention. Administer blood products as ordered. Rationale: Maintains adequate platelet levels. […] Desired Outcomes: The patient will remain free from bleeding episodes. Patient will demonstrate an understanding of bleeding precautions. The patient will maintain stable hemoglobin and platelet levels. […] Nursing Care Plan 4. Impaired Oral Mucous Membrane […] Nursing Diagnosis Statement: Impaired Oral Mucous Membrane related to chemotherapy effects as evidenced by oral pain and mucositis.

Zobacz więcej

dazatynib anemia przewlekła białaczka szpikowa remisja choroby wybroczyny cytometria przepływowa faza akceleracji CML przeszczep szpiku kostnego supresja szpiku kostnego morfologia krwi faza przewlekła CML przeszczep komórek macierzystych ponatynib kariotypowanie kinaza tyrozynowa splenektomia nilotynib gen BCR-ABL translokacja chromosomowa przewlekła białaczka limfocytowa granulocyty terapia celowana chemioterapia imatynib chromosom Philadelphia inhibitory kinazy tyrozynowej ostra białaczka małopłytkowość immunoterapia leukopenia faza blastyczna CML asciminib neutropenia